Table 9ANOVA Modeling HbA1c End Point by Age, Baseline HbA1c, and Assigned Treatment and Change in PRO QOL Scales of SES Distress and the Overall Analogue Health Rating Scale

SourceType III sum of squares df Mean square F P value
Corrected model1085.072a1572.33876.689.000
Intercept539.3011539.301571.741.000
Age120.8931120.893128.165.000
Baseline HbA1c672.1691672.169712.602.000
QOL
 SES distress5.30015.3005.619.018
 Overall analogue health rating15.554115.55416.489.000
Assigned treatment313.8501128.53230.248.000
Error2507.18626580.943
Total159738.8902674
Corrected total3592.257267376.689.000
Parameter estimates: dependent variable: HbA1c end point
Clinical and QOL measures B SE T P value 95% CI
Age−.016.001−11.321.000−.019 to −.013
Baseline HbA1c.465.01726.695.000.431-.499
Scale
 SES Distressb−.030.012−2.370.018−.054 to −.005
 Health Ratingb−.057.014−4.061.000−.085 to −.030

Abbreviations: ANOVA, analysis of variance; HbA1c, hemoglobin A1c; PRO, patient-reported outcome; QOL, quality of life; SES, side effects and symptoms; Sig., significance.

aR2 = 0.302 (adjusted R2 = 0 .298).

bChange in QOL subscale.

From: Benchmarking the Comparative Effectiveness of Diabetes Treatments Using Patient-Reported Outcomes and Socio-Demographic Factors

Cover of Benchmarking the Comparative Effectiveness of Diabetes Treatments Using Patient-Reported Outcomes and Socio-Demographic Factors
Benchmarking the Comparative Effectiveness of Diabetes Treatments Using Patient-Reported Outcomes and Socio-Demographic Factors [Internet].
Testa MA, Su M, Turchin A, et al.
Copyright © 2021. Harvard T.H. Chan School of Public Health. All Rights Reserved.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License which permits noncommercial use and distribution provided the original author(s) and source are credited. (See https://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.